This wouldn't happen at Mediclinic because they are not a pharma company, they're predominantly a "system provider" that makes money of bed-days and theatre time, there are other revenue streams as well, but these are the main ones... Aspen on the other hand, yes, they have risk of the markets, hence diversification in other regions, and they're generic provider, good for emerging markets... every business has risks, but just think about it, healthcare is something of vital importance for us, most medication or care is paid by health insurance and the number of diseases and problems are always changing... back to Mediclinic, the move to Switzerland was great... its a rand hedge and a very good market, aging population that will require more healthcare as they get older, higher income rate, better insurance, yes, some risks exist, but overall it could be quite interesting in years to come... just my thoughts... Personally I would like to see M&A in other European countries in the years to come, once the Swiss market is well represented within Hirslanden, currently in 11 or the 26 cantons, not that they need to be in all, cantons have different legislation and some just might not be very popular for the group...